Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H101 + Camrelizumab in Advanced Pancreatic Cancer
NCT06196671Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Dec 2026
- Primary completion
- Jan 2028
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
A Phase 2 trial of Oncorine in pancreatic adenocarcinoma (PDAC), sponsored by Fudan University. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
Oncorine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06196671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196671.